Abstract Number: 2027 • 2019 ACR/ARP Annual Meeting
Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by autoantibody production and periods of elevated disease activity. Recent studies indicate that along…Abstract Number: 2295 • 2019 ACR/ARP Annual Meeting
Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data
Background/Purpose: Most women with systemic lupus erythematosus (SLE) are diagnosed with the disease in their reproductive ages, but the burden of SLE among women in…Abstract Number: 2541 • 2019 ACR/ARP Annual Meeting
Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment
Background/Purpose: A low glomerular filtration rate (GFR: < 60 mL/min/1.73 m2) is an established risk of hydroxychloroquine (HCQ) retinopathy and is presumably related to higher…Abstract Number: 2737 • 2019 ACR/ARP Annual Meeting
HIF-1α and miR-210 Differential and Lineage-specific Expression in Systemic Lupus Erythematosus
Background/Purpose: Hypoxia inducible factor 1 is a key transcription factor that regulates the cellular response to oxygen stress. In the adaptive immune system, HIF-1α is…Abstract Number: 2883 • 2019 ACR/ARP Annual Meeting
Systemic Lupus Erythematous Risk Alleles Drive Autoimmune Features in a Population Without Diagnosed Autoimmune Diseases
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous disease with > 100 known risk alleles. Some of these risk alleles associate with ACR SLE criteria…Abstract Number: 245 • 2019 ACR/ARP Annual Meeting
Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with high economic burden. This real-world study assessed health care resource utilization (HRU) and costs in a US…Abstract Number: 682 • 2019 ACR/ARP Annual Meeting
Correlation Between the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) and Health-Related Quality of Life (HRQoL) and Other PROs in a Primarily Mestizo Population
Background/Purpose: Disease activity in systemic lupus erythematosus (SLE) is understood differently by patients and physicians; furthermore, there are no reliable measures for patients to assess…Abstract Number: 943 • 2019 ACR/ARP Annual Meeting
A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
Background/Purpose: A pharmacologic intervention that modulates JAK/STAT signaling pathways represents a novel approach for the treatment of Systemic Lupus Erythematosus (SLE). In animal models of…Abstract Number: 1103 • 2019 ACR/ARP Annual Meeting
Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE), Patient Healthcare Utilization and Characteristics by Major Health Insurance Types in the US
Background/Purpose: One study estimated that between 161,000 and 322,000 people in the US had definite or probable SLE, based on data from the period of…Abstract Number: 1565 • 2019 ACR/ARP Annual Meeting
Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is recognized as an independent risk factor for cardiovascular disease (CVD). This study aimed to determine which cardiovascular risk assessment…Abstract Number: 1607 • 2019 ACR/ARP Annual Meeting
Risk Factors for Avascular Necrosis in SLE: A Multivariate Model
Background/Purpose: Systemic lupus erythematosus patients, particularly those who received corticosteroids are at high risk of avascular necrosis (AVN). A past meta-analysis identified other risk factors…Abstract Number: 1782 • 2019 ACR/ARP Annual Meeting
A Human SLE Variant NCF1-R90H Drives Lupus-like Kidney Disease in a Pristane-induced Murine Lupus Model
Background/Purpose: We previously identify a p.Arg90His (p.R90H) substitution encoded in phagocyte neutrophil cytosolic factor (NCF1) as a novel risk variant for SLE, with decreased and…Abstract Number: 2029 • 2019 ACR/ARP Annual Meeting
Aberrant H3K9me3 Modification in Promoter Region Up-regulates cAMP Response Element Modulator Alpha in Systemic Lupus Erythematosus
Background/Purpose: In recent years, accumulating evidences have demonstrated that increased cAMP response element modulator α (CREMα) which can inhibit IL-2 and induce IL-17A in CD4+…Abstract Number: 2516 • 2019 ACR/ARP Annual Meeting
Development of a Biomarker Panel for Prediction of Disease Flares in Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease with a relapsing-remitting course. Uncontrolled lupus flares might lead to organ damage. The routinely performed biomarkers…Abstract Number: 2548 • 2019 ACR/ARP Annual Meeting
Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity
Background/Purpose: Abatacept (ABA) is a fusion protein of the extracellular domain of CTLA4 and human IgG1-Fc, constructed to inhibit B/T cell co-stimulation. Previous studies of…
- « Previous Page
- 1
- …
- 130
- 131
- 132
- 133
- 134
- …
- 150
- Next Page »